featured
Positive Spin on Negative Results: Two mCRPC Studies Presented at ASCO GU
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Dreicer R, Jones R, Oudard S, et al. Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial). Paper presented at: 2014 Genitourinary Cancers Symposium; January 30-February 2, 2014; San Francisco, CA. Abstract 7. J Clin Oncol 32, 2014 (suppl 4; abstr 7).
- Drake CG, Kwon ED, Karim Fizazi K, et al. Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). Paper presented at: 2014 Genitourinary Cancers Symposium; January 30-February 2, 2014; San Francisco, CA. Abstract 2. J Clin Oncol 32, 2014 (suppl 4; abstr 2).